Is biontech a good stock to buy?

The company's average rating score is 2.42, and is based on 5 buy ratings, 7 hold ratings, and no sell ratings. According to analysts' consensus price target of $160.29, BioNTech has a forecasted upside of 63.4% from its current price of $98.12. BioNTech has only been the subject of 3 research reports in the past 90 days.

Who is biontech (bntx)?

BNTX data by YCharts. Based in Germany, BioNTech was originally founded in 2008 and made its debut on the stock market in the U.S. in late 2019. It was a relatively unknown company then, but its coronavirus-related work has helped raise its profile -- as well as improve its financial results.

How much does biontech (ADRs) stock cost?

On Monday morning 08/21/2023 the BioNTech (ADRs) share started trading at the price of $111.36. Compared to the closing price on Friday 08/18/2023 on NAS of $110.36, this is a gain of 0.91%. There are 239.77 M shares outstanding in BioNTech (ADRs), which values the company at $27.21 B. Why did BioNTech stock go up today?

How did biontech perform in the third quarter of 2019?

BioNTech and Pfizer equally share in the gross profits associated with sales of their vaccine. BioNTech also reported a net income of 3.2 billion euros ($3.6 billion); it had recorded a net loss during the third quarter of 2019. Importantly, BioNTech ended the third quarter with 2.4 billion euros ($2.7 billion) in cash and cash equivalents.